1. Home
  2. NICE vs LQDA Comparison

NICE vs LQDA Comparison

Compare NICE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NICE Ltd

NICE

NICE Ltd

HOLD

Current Price

$87.87

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$71.94

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NICE
LQDA
Founded
1986
2004
Country
Israel
United States
Employees
9626
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.5B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NICE
LQDA
Price
$87.87
$71.94
Analyst Decision
Buy
Strong Buy
Analyst Count
13
11
Target Price
$153.46
$41.00
AVG Volume (30 Days)
710.4K
1.7M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.81
EPS
N/A
0.52
Revenue
N/A
$158,320,000.00
Revenue This Year
$10.14
$278.87
Revenue Next Year
$9.62
$57.13
P/E Ratio
$11.21
$125.48
Revenue Growth
N/A
1031.18
52 Week Low
$84.38
$11.85
52 Week High
$175.00
$66.78

Technical Indicators

Market Signals
Indicator
NICE
LQDA
Relative Strength Index (RSI) 38.90 77.57
Support Level $86.40 $31.23
Resistance Level $116.83 N/A
Average True Range (ATR) 3.94 4.10
MACD -0.15 0.26
Stochastic Oscillator 19.06 97.75

Price Performance

Historical Comparison
NICE
LQDA

About NICE NICE Ltd

Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: